Sebastiaan Engelborghs

List of Publications by Year
in descending order

308	28,225	15466	6282
papers	citations	65	158
		h-index	g-index

356	356	356	25023
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	9.4	2,697
2	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	4.9	2,657
3	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1094-1099.	9.4	2,155
4	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
5	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	9.4	1,708
6	Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 2006, 442, 920-924.	13.7	1,386
7	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
8	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
9	A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurology, The, 2012, 11, 54-65.	4.9	565
10	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
11	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
12	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	4.5	374
13	A Practical Guide to Immunoassay Method Validation. Frontiers in Neurology, 2015, 6, 179.	1.1	348
14	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
15	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
16	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomarkers in Medicine, 2012, 6, 419-430.	0.6	280
17	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2012, 8, 65-73.	0.4	271
18	A Pan‐<scp>E</scp>uropean Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. Human Mutation, 2013, 34, 363-373.	1.1	247

#	Article	IF	Citations
19	The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathologica, 2012, 124, 353-372.	3.9	242
20	Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiology of Aging, 2008, 29, 1143-1159.	1.5	217
21	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
22	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	1.2	197
23	Serum biomarker for progranulinâ€associated frontotemporal lobar degeneration. Annals of Neurology, 2009, 65, 603-609.	2.8	195
24	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.4	179
25	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
26	High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Human Molecular Genetics, 2005, 14, 3281-3292.	1.4	156
27	Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology, 2015, 85, 2116-2125.	1.5	151
28	Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P. Neurochemistry International, 2009, 55, 214-218.	1.9	144
29	Alzheimer and Parkinson Diagnoses in Progranulin Null Mutation Carriers in an Extended Founder Family. Archives of Neurology, 2007, 64, 1436.	4.9	143
30	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
31	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.4	134
32	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
33	Risk Factors for Poststroke Depression. Journal of Geriatric Psychiatry and Neurology, 2014, 27, 147-158.	1.2	126
34	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. Lancet Neurology, The, 2015, 14, 814-822.	4.9	124
35	Câ€terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1461-1469.	0.4	117
36	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113

#	Article	IF	Citations
37	Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. Alzheimer's Research and Therapy, 2019, 11, 21.	3.0	113
38	Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1148-1151.	0.9	110
39	No association of CSF biomarkers with APOEÂ4, plaque and tangle burden in definite Alzheimer's disease. Brain, 2007, 130, 2320-2326.	3.7	110
40	TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain, 2011, 134, 808-815.	3.7	110
41	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109
42	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
43	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. NeuroImage: Clinical, 2019, 22, 101771.	1.4	108
44	Depression in Mild Cognitive Impairment is associated with Progression to Alzheimer's Disease: A Longitudinal Study. Journal of Alzheimer's Disease, 2014, 42, 1239-1250.	1.2	107
45	Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. International Journal of Geriatric Psychiatry, 2005, 20, 1028-1037.	1.3	104
46	Differential role of CSF fatty acid binding protein 3, Î±-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. Alzheimer's Research and Therapy, 2017, 9, 52.	3.0	101
47	Biobanking of CSF: International standardization to optimize biomarker development. Clinical Biochemistry, 2014, 47, 288-292.	0.8	97
48	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
49	A 22â€single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid $AÎ²_{42}$. Alzheimer's and Dementia, 2015, 11, 1452-1460.	0.4	96
50	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathologica, 2014, 128, 397-410.	3.9	93
51	Alzheimer's disease CSF biomarkers: clinical indications and rational use. Acta Neurologica Belgica, 2017, 117, 591-602.	0.5	90
52	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.4	90
53	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
54	A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain, 2006, 129, 841-852.	3.7	88

#	Article	IF	Citations
55	*TBK1* Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	1.1	87
56	Clinical features of *TBK1* carriers compared with *C9orf72*, *GRN* and non-mutation carriers in a Belgian cohort. Brain, 2016, 139, 452-467.	3.7	86
57	Distinct Clinical Characteristics of C9orf72 Expansion Carriers Compared With GRN, MAPT, and Nonmutation Carriers in a Flanders-Belgian FTLD Cohort. JAMA Neurology, 2013, 70, 365.	4.5	85
58	Clinical heterogeneity in 3 unrelated families linked to *VCP* p.Arg159His. Neurology, 2009, 73, 626-632.	1.5	84
59	Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis. Journal of Alzheimer's Disease, 2015, 45, 813-822.	1.2	82
60	The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease, 2017, 60, 561-576.	1.2	82
61	Loss of Psychic Self-Activation After Paramedian Bithalamic Infarction. Stroke, 2000, 31, 1762-1765.	1.0	81
62	Cerebrospinal Fluid Aβ1-40 Improves Differential Dementia Diagnosis in Patients with Intermediate P-tau181P Levels. Journal of Alzheimer's Disease, 2013, 36, 759-767.	1.2	79
63	The Middelheim Frontality Score: a behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease. International Journal of Geriatric Psychiatry, 2005, 20, 70-79.	1.3	78
64	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration, 2012, 7, 3.	4.4	77
65	The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochemistry International, 2008, 52, 1052-1060.	1.9	72
66	Monoaminergic neurotransmitter alterations in postmortem brain regions of depressed and aggressive patients with Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2691-2700.	1.5	70
67	Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurology, 2017, 17, 170.	0.8	70
68	A metabolite‐based machine learning approach to diagnose Alzheimer‐type dementia in blood: Results from the European Medical‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	1.8	70
69	Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochemical Research, 2003, 28, 1145-1150.	1.6	69
70	Increased CSF α‐synuclein levels in Alzheimer's disease: Correlation with tau levels. Alzheimer's and Dementia, 2014, 10, S290-8.	0.4	69
71	Association of Cerebrospinal Fluid Prion Protein Levels and the Distinction Between Alzheimer Disease and Creutzfeldt-Jakob Disease. JAMA Neurology, 2015, 72, 267.	4.5	69
72	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2018, 62, 1199-1209.	1.2	69

#	Article	IF	Citations
73	Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study. Alzheimer's Research and Therapy, 2018, 10, 85.	3.0	69
74	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. Acta Neuropathologica, 2018, 135, 827-837.	3.9	68
75	Poststroke depression and its multifactorial nature: Results from a prospective longitudinal study. Journal of the Neurological Sciences, 2014, 347, 159-166.	0.3	67
76	Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochemistry International, 1999, 34, 523-530.	1.9	66
77	Dose dependent effect of APOE ε4 on behavioral symptoms in frontal lobe dementia. Neurobiology of Aging, 2006, 27, 285-292.	1.5	64
78	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	3.0	64
79	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiology of Aging, 2010, 31, 1867-1876.	1.5	63
80	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	3.0	62
81	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.4	62
82	Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochemistry International, 2006, 48, 286-295.	1.9	61
83	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. Neurobiology of Aging, 2017, 51, 177.e9-177.e16.	1.5	60
84	Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Human Mutation, 2009, 30, 1054-1061.	1.1	58
85	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
86	Clinical Evidence of Disease Anticipation in Families Segregating a *C9orf72* Repeat Expansion. JAMA Neurology, 2017, 74, 445.	4.5	56
87	Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer's Research and Therapy, 2020, 12, 58.	3.0	56
88	No correlation between time-linked plasma and CSF Aβ levels. Neurochemistry International, 2009, 55, 820-825.	1.9	53
89	Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 819-833.	1.2	53
90	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. Clinical Chemistry, 2015, 61, 734-743.	1.5	53

#	Article	IF	Citations
91	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	3.9	53
92	How to handle adsorption of cerebrospinal fluid amyloid β (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42 /Aβ40 ratio. , 2017, 13, 885-892.		52
93	Behavioral symptoms in mild cognitive impairment as compared with Alzheimer's disease and healthy older adults. International Journal of Geriatric Psychiatry, 2013, 28, 265-275.	1.3	50
94	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. Journal of Alzheimer's Disease, 2015, 48, 937-948.	1.2	50
95	Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 202-212.	1.8	50
96	Correlations between cognitive, behavioural and psychological findings and levels of vitamin B12 and folate in patients with dementia. International Journal of Geriatric Psychiatry, 2004, 19, 365-370.	1.3	49
97	The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 2015, 7, 7.	3.0	47
98	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. Journal of Alzheimer's Disease, 2016, 54, 383-395.	1.2	47
99	Reduced secreted clusterin as a mechanism for Alzheimer-associated CLU mutations. Molecular Neurodegeneration, 2015, 10, 30.	4.4	46
100	The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 53, 1523-1538.	1.2	46
101	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.4	46
102	Mutated ATP10B increases Parkinson's disease risk by compromising lysosomal glucosylceramide export. Acta Neuropathologica, 2020, 139, 1001-1024.	3.9	46
103	Amyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2013, 35, 137-146.	1.2	45
104	Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. Acta Clinica Belgica, 2014, 69, 17-24.	0.5	44
105	Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Frontiers in Neurology, 2015, 6, 138.	1.1	44
106	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. Journal of Alzheimer's Disease, 2016, 52, 1321-1333.	1.2	44
107	Depressive Symptoms in the Elderly—An Early Symptom of Dementia? A Systematic Review. Frontiers in Pharmacology, 2020, 11, 34.	1.6	43
108	No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration. Neurobiology of Aging, 2011, 32, 754-755.	1.5	42

#	Article	IF	Citations
109	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2018, 10, 31.	3.0	42
110	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	2.4	42
111	Detecting frail, older adults and identifying their strengths: results of a mixed-methods study. BMC Public Health, 2018, 18, 191.	1.2	41
112	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. Journal of Alzheimer's Disease, 2012, 33, 117-131.	1.2	40
113	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
114	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study. PLoS Medicine, 2020, 17, e1003289.	3.9	39
115	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. Clinical Chemistry, 2018, 64, 927-937.	1.5	37
116	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. Acta Neuropathologica, 2019, 137, 901-918.	3.9	37
117	Melatonin levels in the Alzheimer's disease continuum: a systematic review. Alzheimer's Research and Therapy, 2021, 13, 52.	3.0	37
118	Identifying frailty risk profiles of home-dwelling older people: focus on sociodemographic and socioeconomic characteristics. Aging and Mental Health, 2017, 21, 1031-1039.	1.5	36
119	Longitudinal Stability of Cerebrospinal Fluid Biomarker Levels: Fulfilled Requirement for Pharmacodynamic Markers in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 807-822.	1.2	35
120	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. Journal of Alzheimer's Disease, 2016, 55, 19-35.	1.2	35
121	SolCos model–based individual reminiscence for older adults with mild to moderate dementia in nursing homes: a randomized controlled intervention study. Journal of Psychiatric and Mental Health Nursing, 2016, 23, 568-575.	1.2	35
122	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	1.5	34
123	Mutations in glucocerebrosidase are a major genetic risk factor for Parkinson's disease and increase susceptibility to dementia in a Flanders-Belgian cohort. Neuroscience Letters, 2016, 629, 160-164.	1.0	34
124	Follow-Up Study of Susceptibility Loci for Alzheimer's Disease and Onset Age Identified by Genome-Wide Association. Journal of Alzheimer's Disease, 2010, 19, 1169-1175.	1.2	33
125	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.4	33
126	[18]F‑FDG PET, the early phases and the delivery rate of [18]F‑AV45 PET as proxies of cerebral blood flow in Alzheimer's disease: Validation against [15]O‑H_2O PET. Alzheimer's and Dementia, 2019, 15, 1172-1182.	0.4	33

#	Article	IF	Citations
127	Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts. Neurobiology of Aging, 2012, 33, 1004.e17-1004.e20.	1.5	32
128	Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. Aging and Mental Health, 2015, 19, 247-257.	1.5	32
129	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	1.5	30
130	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	4.4	30
131	Behavioural and neuropsychological correlates of frontal lobe features in dementia. Psychological Medicine, 2006, 36, 1173-1182.	2.7	29
132	Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis. International Journal of Geriatric Psychiatry, 2015, 30, 864-869.	1.3	29
133	Phenotypic characteristics of Alzheimer patients carrying an *ABCA7* mutation. Neurology, 2016, 86, 2126-2133.	1.5	29
134	Validation of the Semiquantitative Static SUVR Method for ^{18}F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. Journal of Nuclear Medicine, 2017, 58, 1483-1489.	2.8	29
135	BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. Journal of Alzheimer's Disease, 2017, 56, 1437-1449.	1.2	28
136	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
137	Encephalitis associated with the SARS-CoV-2 virus: A case report. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2020, 22, 100821.	0.2	27
138	Validation of the AD-CSF-Index in Autopsy-Confirmed Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2014, 41, 903-909.	1.2	26
139	CFAI-Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument. International Journal of Geriatric Psychiatry, 2018, 33, 941-947.	1.3	25
140	Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm. NeuroImage: Clinical, 2020, 26, 102243.	1.4	25
141	Functional anatomy, vascularisation and pathology of the human thalamus. Acta Neurologica Belgica, 1998, 98, 252-65.	0.5	25
142	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. Journal of Alzheimer's Disease, 2016, 55, 159-170.	1.2	23
143	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. Neurobiology of Aging, 2019, 79, 131-141.	1.5	23
144	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. Acta Neuropathologica Communications, 2021, 9, 25.	2.4	23

#	Article	IF	Citations
145	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.4	23
146	The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer's Disease. Molecular Diagnosis and Therapy, 2012, 16, 135-141.	1.6	22
147	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. Frontiers in Neuroscience, 2019, 13, 757.	1.4	22
148	Tau Monoclonal Antibody Generation Based on Humanized Yeast Models. Journal of Biological Chemistry, 2015, 290, 4059-4074.	1.6	21
149	Mutated <i>CTSF</i> in adult-onset neuronal ceroid lipofuscinosis and FTD. Neurology: Genetics, 2016, 2, e102.	0.9	21
150	Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. Frontiers in Psychiatry, 2021, 12, 707580.	1.3	21
151	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 97-106.	1.2	20
152	Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. Alzheimer's Research and Therapy, 2019, 11, 73.	3.0	20
153	Limited engagement in, yet clear preferences for advance care planning in young-onset dementia: An exploratory interview-study with family caregivers. Palliative Medicine, 2019, 33, 1166-1175.	1.3	20
154	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. European Journal of Neurology, 2021, 28, 2147-2155.	1.7	20
155	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	1.7	20
156	Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Revue Neurologique, 2013, 169, 709-714.	0.6	19
157	Psychosis associated behavioral and psychological signs and symptoms in mild cognitive impairment and Alzheimer's dementia. Aging and Mental Health, 2015, 19, 818-828.	1.5	19
158	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	1.5	19
159	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	1.3	19
160	Associating Alzheimer's disease pathology with its cerebrospinal fluid biomarkers. Brain, 2022, 145, 4056-4064.	3.7	19
161	Relation between frontal lobe symptoms and dementia severity within and across diagnostic dementia categories. International Journal of Geriatric Psychiatry, 2010, 25, 1186-1195.	1.3	18
162	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. Journal of Alzheimer's Disease, 2016, 52, 51-64.	1.2	18

#	Article	IF	Citations
163	Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis. Neurobiology of Aging, 2018, 69, 292.e7-292.e14.	1.5	18
164	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). NeuroImage: Clinical, 2019, 23, 101846.	1.4	18
165	Validation of soluble amyloid‑β precursor protein assays as diagnostic <scp>CSF</scp> biomarkers for neurodegenerative diseases. Journal of Neurochemistry, 2016, 137, 112-121.	2.1	17
166	Clinical variability and onset age modifiers in an extended Belgian GRN founder family. Neurobiology of Aging, 2018, 67, 84-94.	1.5	17
167	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). Journal of Alzheimer's Disease, 2018, 63, 1509-1522.	1.2	17
168	Exploring Cognitive Frailty: Prevalence and Associations with Other Frailty Domains in Older People with Different Degrees of Cognitive Impairment. Gerontology, 2020, 66, 55-64.	1.4	17
169	Amyloid-β1‑43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. Alzheimer's Research and Therapy, 2020, 12, 108.	3.0	17
170	Next Generation Brain Health Depends on Early Alzheimer Disease Diagnosis: From a Timely Diagnosis to Future Population Screening. Journal of the American Medical Directors Association, 2016, 17, 452-453.	1.2	16
171	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	1.5	16
172	Impact of hearing loss and vestibular decline on cognition in Alzheimer's disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECkO). BMJ Open, 2020, 10, e039601.	0.8	16
173	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	1.7	16
174	Associations of Bilateral Vestibulopathy With Cognition in Older Adults Matched With Healthy Controls for Hearing Status. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 731.	1.2	16
175	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. Journal of Alzheimer's Disease, 2015, 45, 1039-1043.	1.2	15
176	Alzheimer's disease and driving: review of the literature and consensus guideline from Belgian dementia experts and the Belgian road safety institute endorsed by the Belgian Medical Association. Acta Neurologica Belgica, 2017, 117, 811-819.	0.5	15
177	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	1.5	15
178	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12314.	1.2	15
179	Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council. Journal of Alzheimer's Disease, 2019, 69, 989-1001.	1.2	14
180	A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease. PLoS ONE, 2017, 12, e0189155.	1.1	14

#	Article	IF	Citations
181	Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains. Acta Neuropathologica Communications, 2015, 3, 68.	2.4	13
182	EEG Dominant Frequency Peak Differentiates Between Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2016, 55, 53-58.	1.2	13
183	Randomized controlled trial to evaluate a prevention program for frail community-dwelling older adults: a D-SCOPE protocol. BMC Geriatrics, 2018, 18, 194.	1.1	13
184	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
185	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
186	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. Neurobiology of Aging, 2021, 108, 99-109.	1.5	13
187	Headache As Only Symptom in Multiple Cervical Artery Dissection. Headache, 2001, 41, 509-511.	1.8	12
188	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. Journal of Alzheimer's Disease, 2018, 63, 373-381.	1.2	12
189	Callosal circularity as an early marker for Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 516-526.	1.4	12
190	Techniques, Contraindications, and Complications of CSF Collection Procedures. , 2015, , 35-57.		12
191	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimerâ€™s Disease and Controls. Frontiers in Aging Neuroscience, 2021, 13, 746982.	1.7	12
192	Impact of frequent cerebrospinal fluid sampling on AÎ² levels: systematic approach to elucidate influencing factors. Alzheimer's Research and Therapy, 2016, 8, 21.	3.0	11
193	Selecting AÎ² isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. Biomarkers in Medicine, 2017, 11, 169-178.	0.6	11
194	No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimer's Research and Therapy, 2017, 9, 49.	3.0	11
195	Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review. Ear and Hearing, 2021, 42, 1119-1126.	1.0	11
196	A qualitative study with people with young-onset dementia and their family caregivers on advance care planning: A holistic, flexible, and relational approach is recommended. Palliative Medicine, 2022, 36, 964-975.	1.3	11
197	Higher susceptibility to 6ÂHz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease. Epilepsia, 2022, 63, 2703-2715.	2.6	11
198	Experimental autoimmune encephalomyelitis: An animal model for multiple sclerosis. Neuroscience Research Communications, 2000, 26, 193-206.	0.2	10

#	ARTICLE	IF	CITATIONS
199	Multicenter Analytical Validation of Aβ40 Immunoassays. Frontiers in Neurology, 2017, 8, 310.	1.1	10
200	Extended FTLD pedigree segregating a Belgian GRN-null mutation: neuropathological heterogeneity in one family. Alzheimer's Research and Therapy, 2018, 10, 7.	3.0	10
201	Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2021, 80, 1629-1642.	1.2	10
202	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. Neurobiology of Aging, 2021, 106, 307.e1-307.e7.	1.5	10
203	Comparing Advance Care Planning in Young-Onset Dementia in the USA vs Belgium: Challenges Partly Related to Societal Context. Journal of the American Medical Directors Association, 2020, 21, 851-857.	1.2	10
204	The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. Journal of the Neurological Sciences, 2012, 322, 197-199.	0.3	9
205	Pre-analytical stability of novel cerebrospinal fluid biomarkers. Clinica Chimica Acta, 2019, 497, 204-211.	0.5	9
206	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. Journal of Alzheimer's Disease, 2019, 68, 1151-1159.	1.2	9
207	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	1.7	9
208	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	4.1	9
209	Meanings of Care Convoys: The Structure, Function, and Adequacy of Care Networks Among Frail, Community-Dwelling Older Adults. Qualitative Health Research, 2020, 30, 583-597.	1.0	8
210	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. Neurobiology of Aging, 2021, 104, 105.e1-105.e6.	1.5	8
211	iPSC-derived cortical neurons to study sporadic Alzheimer disease: A transcriptome comparison with post-mortem brain samples. Toxicology Letters, 2022, 356, 89-99.	0.4	8
212	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. Acta Neurologica Belgica, 2015, 115, 547-555.	0.5	7
213	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
214	CSF and Blood Neurofilament Levels in Athletes Participating in Physical Contact Sports. Neurology, 2021, 96, 705-715.	1.5	7
215	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. Journal of Alzheimer's Disease, 2021, 83, 623-639.	1.2	7
216	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	1.4	7

#	Article	IF	Citations
217	Severe bilateral subdural hematomas as a complication of diagnostic lumbar puncture for possible Alzheimer's disease. Clinical Neurology and Neurosurgery, 2017, 152, 95-96.	0.6	5
218	Stronger Correlations between Neurophysiological and Peripheral Disease Biomarkers Predict Better Prognosis in Two Severe Diseases. Journal of Clinical Medicine, 2020, 9, 26.	1.0	5
219	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. Frontiers in Molecular Biosciences, 2020, 7, 48.	1.6	5
220	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. Neurobiology of Aging, 2021, 99, 100.e17-100.e23.	1.5	5
221	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. Journal of Neuropathology and Experimental Neurology, 2021, 80, 313-324.	0.9	5
222	Apraxic agraphia following thalamic damage: Three new cases. Brain and Language, 2015, 150, 153-165.	0.8	4
223	Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap. Frontiers in Neuroscience, 2021, 15, 781322.	1.4	4
224	Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats. Arzneimittelforschung, 1998, 48, 713-6.	0.5	4
225	Recurrent transient ischemic attacks in a 15-year-old boy with beta-thalassemia minor and thrombophilia. Contribution of perfusion SPECT to clinical diagnosis. Acta Neurologica Belgica, 2003, 103, 99-102.	0.5	4
226	5-HT2A receptor polymorphism may modulate antipsychotic treatment response in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2004, 19, 1108-1109.	1.3	3
227	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. Acta Neurologica Belgica, 2020, 120, 1157-1163.	0.5	3
228	[P2–363]: EARLY FRAME 18F-AV45 AND 18F-FDG-PET AS PROXIES OF CBF: COMPARISON TO 15O-H2O PET DATA. Alzheimer's and Dementia, 2017, 13, P763.	0.4	2
229	A family-based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis. Alzheimer's and Dementia, 2020, 16, e047212.	0.4	2
230	No association of CpG SNP rs9357140 with onset age in Belgian C9orf72 repeat expansion carriers. Neurobiology of Aging, 2021, 97, 145.e1-145.e4.	1.5	2
231	Family-based exome sequencing identifies RBM45 as a possible candidate gene for frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiology of Disease, 2021, 156, 105421.	2.1	2
232	P4-232: A monoclonal antibody-based elisa for neurogranin. , 2015, 11, P869-P869.		1
233	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
234	P4-249: Admetrix: A new method for atrophy quantification in Alzheimer's disease. , 2015, 11, P876-P876.		1

#	ARTICLE	IF	CITATIONS
235	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
236	P1â€407: Cognitive Frailty: A New Domain Added to The Comprehensive Frailty Assessment. Alzheimer's and Dementia, 2016, 12, P590.	0.4	1
237	O1-11-02: Combination of Cerebrospinal Fluid H-FABP and Core Alzheimer's Disease Biomarkers Improves the Differential Diagnosis of Neurodegenerative Disorders. , 2016, 12, P201-P202.		1
238	[P4â€"075]: THE <i>MAPT</i> P.ARG406TRP IS A FOUNDER MUTATION IN BELGIUM AND PRESENTS WITH AN ALZHEIMER DISEASE DEMENTIAâ€LIKE PHENOTYPE. Alzheimer's and Dementia, 2017, 13, P1286.	0.4	1
239	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.4	1
240	3xTg Alzheimerâ€™s disease mice are more susceptible to induced seizures. Alzheimer's and Dementia, 2020, 16, e044096.	0.4	1
241	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.4	1
242	Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimerâ€™s Disease but Are Not Correlated with Cognitive Decline. Journal of Alzheimer's Disease, 2021, 83, 693-704.	1.2	1
243	Adults with cerebral palsy and Alzheimer disease: a missing link?. Developmental Medicine and Child Neurology, 2022, 64, 284-284.	1.1	1
244	Biological and genetic markers of sporadic Alzheimer's disease. Acta Medica Okayama, 2001, 55, 55-63.	0.1	1
245	O1-03-01: In-depth molecular genetic analysis of CLU in Alzheimer's disease. , 2010, 6, S73-S74.		0
246	O1-04-04: ANALYSIS OF SQSTM1 IN PATIENTS WITH EARLY-ONSET ALZHEIMER'S DISEASE. , 2014, 10, P135-P136.		0
247	P1-053: OLFACTORY RECEPTOR COPY NUMBER VARIATION INVOLVED IN ALZHEIMER'S DISEASE. , 2014, 10, P322-P323.		0
248	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
249	O4-11-03: Limited impact of CSF biomarkers variability on clinical diagnosis in autopsy-confirmed Alzheimer's disease. , 2015, 11, P296-P297.		0
250	P4-248: Resting state functional MRI as a possible biomarker for Alzheimer's disease: An innovative approach for robust extraction of the default mode network. , 2015, 11, P876-P876.		0
251	P3-017: Rare variants in PLD3 do not increase risk in a belgian cohort of early-onset Alzheimer dementia patients. , 2015, 11, P626-P626.		0
252	P4-194: The identification of high-penetrant loss-of-function mutations in abca7 in Alzheimer's disease. , 2015, 11, P854-P854.		0

#	Article	IF	Citations
253	P2-299: Brief Neuropsychological Screening Tests for the Detection of Alzheimer's Disease in an Early Phase: A Systematic Review. , 2016, 12, P748-P748.		0
254	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
255	P4-194: Blood Flow-Independent Quantification of [18F]-AV45 PET Using Model-Based Kinetics With a Metabolite-Corrected Arterial Input Function. , 2016, 12, P1097-P1098.		0
256	P1â€176: CSF Exploratory Biomarker Study for (DIFFERENTIAL) Diagnosis of Frontotemporal Lobar Degeneration. Alzheimer's and Dementia, 2016, 12, P471.	0.4	0
257	P1â€320: Volumetric Brain MRI of Different Regions, Including The Hippocampus, in The Alzheimerâ€™s Disease Spectrum: A Systematic Review. Alzheimer's and Dementia, 2016, 12, P547.	0.4	0
258	P2-153: Diagnostic Performance of Non-Phosphorylated TAU Fraction (PTAU REL) in CSF as Biomarker for Differential Dementia Diagnosis. , 2016, 12, P672-P673.		0
259	P3â€258: Resting State Functional Mri in Alzheimerâ€™S Disease: an Innovative Approach ror Robust Extraction of the Default Mode Network. Alzheimer's and Dementia, 2016, 12, P930.	0.4	0
260	P4â€120: Increased CSF Levels of Biomarkers for Neurodegeneration in FTLDâ€GRN Mutation Carriers. Alzheimer's and Dementia, 2016, 12, P1058.	0.4	0
261	O4â€09â€03: Eeg Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. Alzheimer's and Dementia, 2016, 12, P354.	0.4	0
262	P1-170: A Decade of Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease in Belgium. , 2016, 12, P467-P468.		0
263	P4â€314: Discordance Between Amyloidâ€PET and CSF Amyloidâ€Î² for Diagnosing Alzheimerâ€™S Disease in a Clinical Setting. Alzheimer's and Dementia, 2016, 12, P1154.	0.4	0
264	P4â€322: CSF Biomarkers to Predict Rate of Cognitive Decline in Alzheimerâ€™S Disease. Alzheimer's and Dementia, 2016, 12, P1157.	0.4	0
265	P4â€324: Plasma Neurofilament Light Concentration Predicts Longâ€Term Outcome an Acute Stroke. Alzheimer's and Dementia, 2016, 12, P1158.	0.4	0
266	P4-159: Screening and Recruitment Experience When Using Biomarker-Based Population Definition in Alzheimerâ€™s Disease Studies. , 2016, 12, P1075-P1076.		0
267	P3â€209: Impact of Biomarkers On Diagnostic Confidence in Clinical Assessment of Patients with Suspected Alzheimer's Disease and High Diagnostic Uncertainty: An EADC Study. Alzheimer's and Dementia, 2016, 12, P904.	0.4	0
268	[P4â€"069]: A PROSPECTIVE NEUROGENETIC STUDY ON EARLYâ€ONSET DEMENTIA IN PATIENTS WITH UNCLEAR INITIAL DIAGNOSIS OF DEGENERATIVE DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1284.	0.4	0
269	[P1â€"237]: DIFFERENTIAL ROLE OF CSF FATTY ACID BINDING PROTEIN 3, Î±â€SYNUCLEIN AND ALZHEIMER's DISEASE CORE BIOMARKERS IN LEWY BODY DISORDERS AND ALZHEIMER's DEMENTIA. Alzheimer's and Dementia, 2017, 13, P334.	0.4	0
270	[P4â€"239]: FDGâ€PET POWER TO PREDICT MEMORY DECLINE IN ALZHEIMER's DISEASE DEPENDS ON DISEASE PHASE AND AMYLOID AND TAU STATUS. Alzheimer's and Dementia, 2017, 13, P1366.	0.4	0

#	Article	IF	Citations
271	[P1–289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOID–PET) IN THE EMIF–AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
272	[P1–387]: CHARACTERIZATION OF SUSPECTED NON–ALZHEIMER's DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT USING NEUROIMAGING. Alzheimer's and Dementia, 2017, 13, P414.	0.4	0
273	[P2–116]: TRANSCRIPTOME ANALYSIS IN BLOOD AND BRAIN IDENTIFIES GENE EXPRESSION REGULATION AND CORRESPONDING QUANTITATIVE TRAIT LOCI IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P651.	0.4	0
274	[P2–211]: AMYLOID–Î²42 (AÎ²42) DIFFERENTIALLY CORRELATES WITH CSF TOTAL AND HYPERPHOSPHORYLATED TAU IN AN AMYLOID–POSITIVE VERSUS AMYLOID–NEGATIVE EARLY PRODROMAL AND ASYMPTOMATIC AT–RISK FOR AD POPULATION. Alzheimer's and Dementia, 2017, 13, P690.	0.4	0
275	[O2–13–05]: DELETERIOUS <i>ABCA7</i> MUTATIONS CONTRIBUTE TO EARLY–ONSET ALZHEIMER's DISEASE AND ARE SUBJECT TO TRANSCRIPT RESCUE MECHANISMS. Alzheimer's and Dementia, 2017, 13, P589.	0.4	0
276	P2–270: INCREASED CSF AMYLOID–Î² 1–38 AND 1–40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	0.4	0
277	P3–233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF–AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
278	P2–228: PRE–ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P755.	0.4	0
279	O4–01–01: IN–DEPTH ANALYSIS OF AN ABCA7 VNTR IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1400.	0.4	0
280	F1–02–04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF–AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.4	0
281	P3–128: EXPLORING THE MOLECULAR MECHANISM OF NEURONAL HYPEREXCITABILITY IN DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1116.	0.4	0
282	P3–409: PERFORMANCE EVALUATION OF AUTOMATIC BRAIN MRI SUBSTRUCTURE SEGMENTATION WITH ICOBRAIN. Alzheimer's and Dementia, 2018, 14, P1260.	0.4	0
283	F1–02–02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
284	F1–02–01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENT–LIGHT AND YKL–40 TO AÎ², APOE Îµ4 AND COGNITION: RESULTS FROM THE EMIF–AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
285	P2–458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIF–AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0
286	F1–02–03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIF–AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.4	0
287	P4–525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.4	0
288	O5–05–03: ASSOCIATIONS BETWEEN CEREBROSPINAL FLUID NEURODEGENERATIVE MARKERS, NEUROFILAMENT–LIGHT AND TOTAL TAU AND CEREBROVASCULAR IMAGING MARKERS. Alzheimer's and Dementia, 2019, 15, .	0.4	0

#	Article	IF	Citations
289	ICâ€Pâ€130: ICOBRAIN DM: A NEW METHOD FOR HIPPOCAMPUS AND BRAIN LOBE SEGMENTATION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P107.	0.4	0
290	Biomarker counseling, disclosure of diagnosis, and followâ€up in patients with mild cognitive impairment: A European survey of EADC centers. Alzheimer's and Dementia, 2020, 16, e039026.	0.4	0
291	Recessive missense variants in VWA2 increase risk of developing Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e039791.	0.4	0
292	ABCA7 mutations are major contributors to Alzheimerâ€™s disease in Belgian patients. Alzheimer's and Dementia, 2020, 16, e040227.	0.4	0
293	ABCA7 PTC mutation carriers present with Alzheimerâ€™s disease pathology and cerebral amyloid angiopathy. Alzheimer's and Dementia, 2020, 16, e041513.	0.4	0
294	Cerebrospinal fluid amyloid status and affective symptoms in mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e041961.	0.4	0
295	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e042739.	0.4	0
296	DNA methylation differences associated with peripheral biomarkers in the EMIFâ€AD cohort. Alzheimer's and Dementia, 2020, 16, e045853.	0.4	0
297	Diagnostic Evaluation of Dementia. , 2021, , 31-55.		0
298	Lumbar Puncture: Consensus Guidelines. Neuromethods, 2021, , 129-135.	0.2	0
299	Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study. SSRN Electronic Journal, 0, , .	0.4	0
300	Development and analytical performance testing of a novel sTREM2 ELISA method to support drug development. Alzheimer's and Dementia, 2021, 17, .	0.4	0
301	Development and analytical characterization of novel tau Simoa assays targeting fullâ€length tau in CSF and midâ€tau in CSF and plasma. Alzheimer's and Dementia, 2021, 17, .	0.4	0
302	Title is missing!. , 2020, 17, e1003289.		0
303	Title is missing!. , 2020, 17, e1003289.		0
304	Title is missing!. , 2020, 17, e1003289.		0
305	Title is missing!. , 2020, 17, e1003289.		0
306	Title is missing!. , 2020, 17, e1003289.		0

#	Article	IF	Citations
307	Title is missing!. , 2020, 17, e1003289.		0
308	Title is missing!. , 2020, 17, e1003289.		0